Circle raised $92.5 million to accelerate its cyclin D1 program, advancing the preclinical lead CID-165 ahead of an earlier priority asset. The funding was prompted by deeper breast cancer combination data, with the company positioning CID-165 as the next internal clinical focus for combination approaches.